



PRESS RELEASE

AMOEBEA signs a Letter of Intent with MOMAR *For the distribution of BIOMEBA on a new US territory*

Lyon (France), Atlanta (GA, USA), July 27th, 2017 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water and wound care applications, announced today that it has signed a Letter of Intent (LOI) with MOMAR Inc. prior to entering into a definitive agreement regarding the distribution of its product in the United States pending marketing authorization.

The signature of this agreement allows AMOEBA to extend its commercial cover for the distribution of the green biocide BIOMEBA on the South-East states of the United States including mainly agri-food and aerospace industries.

“Since MOMAR, Inc. was established in 1947, we have grown continuously through our industry-leading research and development, our field force with their problem-solving drive, and by forming partnerships, such as the one we entered with AMOEBA. Our customers require solutions that provide extensive system protection options, while maintaining a desire to reduce environmental impact. MOMAR, Inc. is excited to partner with AMOEBA to bring this new wave of green technology innovation to our customers, to provide a unique path to control microbiological growth in their industrial water treatment processes.” said **George GRABOW, GENERAL MANAGER of the AquaTrol Division of MOMAR, INC.**

“Thanks to the signature of this agreement with MOMAR, we are actively pursuing our commercial development on the American territory in strengthening our presence on the southern states of the US which covers a large number of companies looking for sustainable solutions in industrial water treatment.” stated **Fabrice PLASSON, CEO of AMOEBA.**



About MOMAR:

Momar, Inc., is a specialty manufacturer of general maintenance and sanitation chemicals. Founded in Atlanta, Georgia, in 1947, our family-owned and operated company continues to grow with industry-leading research and advanced product development. From our original foundation of 150 general and specialized maintenance chemicals, we have grown to proudly offer over 5,000 MRO (Maintenance, Repair, and Operations) related products, systems, and services. Through our Eight Divisions, we specialize as a total fluids manufacturer and supplier. We provide our customers with virtually every product or service available in the areas of maintenance chemicals and equipment, lubrication, water and waste water treatment, food processing chemicals, mineral handling, dust suppression, specialty hardware, industrial safety equipment, and expert application services. Our AquaTrol Division is the water treatment division of Momar. From this Division, we formulate and manufacture a wide variety of advanced-technology water treatment chemicals and systems for a wide range of water processing equipment. Our water treatment products protect against corrosion, scaling, and fouling. They range from potable water corrosion inhibitors to waste treatment products and solutions. We are committed to energy efficiency and water savings, offering a full line of environmentally-responsible products as well as an in-house laboratory for testing. More information on www.momar.com.



About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating waterborne bacterial risk in water treatment and wound care applications. Our solutions represent alternatives to chemical products widely used in the cooling water treatment and the wound care market. In a global market for chemical biocides estimated to be worth EUR 21 bn⁽¹⁾ AMOEBA is focusing on the industrial cooling tower application estimated at EUR 1.7 bn⁽²⁾. Similarly, in a global wound care market estimated at EUR 15.2bn⁽³⁾, AMOEBA is targeting the chronic wound care market in the USA, estimated to be worth EUR 751 million⁽⁴⁾. The use of Willaertia magna C2c Maky in health care products will be subject to FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological biocide for water treatment, BIOMEBA, has not yet been granted marketing authorization in the USA, Europe and Canada. AMOEBA is taking the required regulatory steps to be granted marketing authorization in those regions for the use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. More information on www.amoeba-biocide.com.

(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

(3) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016

(4) BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

Contacts:

Amoéba
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
gasparetto@actifin.fr